Double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia (SHASTA-3 study)
The purpose of this clinical research study is to look at how safe and effective ARO-APOC3 is at lowering triglycerides in people with hypertriglyceridemia. Hypertriglyceridemia is a condition where there is a high level of a certain kind of fat (called triglycerides) in the blood. The human body needs some triglycerides for good health. If […]
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism
The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism. This study will compare the effect of Armour Thyroid on hypothyroidism and its safety with synthetic drug T4 (Levothyroxine). The number of FDA-approved and commercially available options for the treatment of hypothyroidism are limited. Currently, […]
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index (BMI) ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH OUTCOMES)
This study is being done to see how safe an investigational drug is and how well it will work to help people with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 and heart related and/or kidney related disease. “Investigational” means that the drug being tested has not been approved for routine […]
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus
The study drug ZT-01 is designed to inhibit somatostatin, a hormone that inhibits the glucagon response to hypoglycemia. Thus, ZT-01 may be able to restore glucagon production to prevent hypoglycemia, which could improve both health and quality of life in people with T1DM. The purpose of this study is:
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
This trial is testing an experimental drug called MK-0616 in people with high cardiovascular risk. The purpose of this trial is to: A placebo looks like the trial drug, but it has no active ingredients.
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a).
The main purpose of this study is to learn more about lepodisiran which is an experimental treatment for elevated lipoprotein (a) (Lp[a]); which is an increase in a type of fat in your blood that is not good for your health. The study aims to learn:
